Bipolar medicines require different monitoring
“Mood stabiliser” is a useful umbrella term, not proof that lithium, lamotrigine, valproate and antipsychotics do the same job. Treatment depends on whether the current problem is mania, bipolar depression or prevention of future episodes. Each medicine has distinct laboratory, metabolic, skin-reaction, pregnancy and interaction concerns, and abrupt stopping can precipitate relapse. The monitoring plan is therefore part of the treatment choice.
Key takeaways
- A medicine useful for mania may not treat bipolar depression in the same way, and maintenance evidence differs again.
- Lithium requires blood levels plus kidney, thyroid and calcium monitoring; illness, sweating, dehydration and interacting medicines can raise toxicity risk.
- Lamotrigine rash, antipsychotic metabolic or movement effects and valproate pregnancy restrictions require different safety conversations rather than one “mood stabiliser check”.
Why does the phase of bipolar disorder matter?
Bipolar disorder includes episodes of mania or hypomania and depression, with periods of recovery or ongoing symptoms between episodes. A medicine may be selected for an acute episode, longer-term relapse prevention, or both. The person’s previous episode pattern and response are therefore central.
For example, lamotrigine may have a role in bipolar depression and maintenance but is not an acute antimanic medicine. Antipsychotics have medicine-specific roles across mania, depression or maintenance. Lithium has evidence across acute and long-term care but only works safely within a monitored exposure range. A catalogue cannot infer the phase from the diagnosis label.
NICE’s current bipolar-disorder recommendations organise treatment by phase and explicitly connect each medicine class to its own monitoring and stopping requirements.
How do the monitoring questions differ?
| Medicine group | Possible role in a specialist plan | Monitoring or warning focus |
|---|---|---|
| Lithium | Mania treatment and long-term relapse prevention in selected patients | Blood lithium level, kidney and thyroid function, calcium, hydration, interactions and toxicity symptoms |
| Lamotrigine | Bipolar depression or maintenance in selected patients | Slow prescribed titration, new rash or mucosal symptoms, interactions and pregnancy-related level changes |
| Antipsychotics such as quetiapine or olanzapine | Medicine-specific roles in mania, bipolar depression or maintenance | Weight, waist, blood pressure, glucose, lipids, sedation, movement and hormonal effects |
| Valproate/divalproex | Selected acute or maintenance use under substantial reproductive-safety restrictions | Pregnancy prevention, liver and blood effects, weight, interactions and medicine-specific safety controls |
The same ingredient may also be used for epilepsy or another condition, with different treatment goals. Never assume that a friend’s dose, blood target or monitoring interval applies to bipolar treatment.
Why is lithium monitoring unusually visible?
Lithium has a narrow therapeutic range: too little may not provide the intended effect, while excessive exposure can become toxic. Blood levels are checked after initiation and dose changes and then periodically once stable. Kidney function, thyroid function, calcium and weight are also monitored because clinically important changes can emerge over time.
Fluid and sodium balance affect lithium. Singapore heat, fever, heavy sweating, vomiting or diarrhoea can reduce fluid volume and raise risk. The current HealthHub lithium guide advises maintaining hydration and contacting a clinician during illnesses that cause heavy sweating, vomiting or diarrhoea.
Interactions matter. NSAID painkillers, some blood-pressure medicines and diuretics can alter lithium handling. Do not solve this by skipping lithium or another prescribed medicine independently; ask a clinician or pharmacist to check the exact products. Coarse tremor, worsening vomiting or diarrhoea, marked unsteadiness, confusion, severe drowsiness, blurred vision or muscle weakness can signal excessive lithium and need urgent advice.
What is different about lamotrigine?
Lamotrigine does not usually require routine blood-level monitoring in stable bipolar treatment. Its distinctive early concern is rash, including rare severe skin reactions. Dose escalation is deliberately gradual, and interrupted treatment may require a clinician to decide how it should be restarted rather than resuming the previous dose automatically.
Contact a clinician immediately about a new rash during titration, especially with blistering, peeling, mouth or eye sores, facial swelling, fever or feeling unwell. HealthHub’s lamotrigine guide flags Stevens–Johnson syndrome and toxic epidermal necrolysis as rare serious reactions.
Valproate can raise lamotrigine exposure, while some other medicines can lower it. Pregnancy can substantially change lamotrigine levels. These are reasons for coordinated review, not self-adjustment.
What does antipsychotic monitoring add?
Antipsychotics differ in appetite, weight, glucose, lipid, sedation, blood-pressure, movement and prolactin effects. Monitoring therefore includes physical measurements and blood tests as well as sleep, alertness, restlessness, tremor, stiffness, menstrual or sexual changes and everyday function. See the fuller comparison of antipsychotic formulations and monitoring.
NICE recommends recording weight or BMI frequently at initiation, checking pulse and blood pressure after dose changes, and checking glucose/HbA1c and lipids after the early treatment period, with continuing systematic review. An “acceptable” weight does not rule out glucose or lipid change, and normal laboratory results do not dismiss disabling movement effects.
Why does valproate require a separate reproductive-safety discussion?
Valproate exposure during pregnancy carries a high risk of congenital malformations and developmental harm. Singapore’s HSA states that valproate is contraindicated during pregnancy for bipolar disorder and that use in women of childbearing potential is restricted by a pregnancy-prevention programme when alternatives are ineffective or not tolerated. See the HSA safety communication.
Pregnancy planning should prompt specialist review before conception, but valproate, lithium, lamotrigine or an antipsychotic should not be stopped abruptly without a coordinated plan. Untreated mania, depression or psychosis also carries serious risk, and the postnatal period can be a high-risk time for relapse.
What changes the answer?
- Current phase and past episodes. Mania, bipolar depression and maintenance require different evidence and urgency.
- Previous benefit and adverse effects. A documented individual response may outweigh broad class comparisons.
- Kidney, thyroid, liver and metabolic health. These change medicine suitability and monitoring intensity.
- Pregnancy, contraception and breastfeeding. Risks are medicine-specific and need preconception planning where possible.
- Heat, illness and interactions. Dehydration and interacting medicines are particularly important with lithium.
- Adherence and formulation. Daily routine, modified-release tablets, missed doses and the ability to attend blood tests affect safety.
Which mood or safety changes need urgent help?
Urgent assessment is needed for inability to stay safe, suicidal intent, severe agitation or aggression, several nights with little or no sleep alongside escalating energy or risky behaviour, hallucinations, severe confusion or inability to care for basic needs. Suspected lithium toxicity, a severe lamotrigine rash, overdose, seizure or neuroleptic malignant syndrome also requires urgent care.
Bring an up-to-date medicine list, blood-test record, recent dose or brand changes, missed doses and a short sleep and mood timeline to reviews. In Singapore, call 995 for immediate danger. National mindline 1771 and Samaritans of Singapore 1767 provide 24-hour support. The bipolar-disorder condition page can organise medicine names but cannot provide a personal combination or stopping plan.
Sources
- NICE: Bipolar disorder—assessment and management recommendations.
- NICE: Antenatal and postnatal mental-health recommendations.
- HealthHub Singapore: Lithium.
- HealthHub Singapore: Lamotrigine.
- Singapore Health Sciences Authority: Valproate—restrictions on use.
- HealthHub MindSG: Preventing self-harm and suicide—helplines.
